Table 3. Selected cost parameters.

Parameter	Base Case Value	Range for Sensitivity Analysis	Ref.
Costs (2009 USD)
Chest radiograph	1	0.30–3	[35]
TB sputum stain and culture	17	6–50	[33], [35]
Liver function test	9	3–27	[33]
DOT visit	1	0.30–3	[35]
IPT Regimensa
Total 6EH course	40	19–133	[33], [34], [35]
Total 36H course	90	47–363	[33], [34], [35]
Total 6H course	20		[33], [34], [35]
Total 3RH course	25		[33], [34], [35]
Total 3RPTH course	180		[33], [34], [35], [57]
Active TB treatmentb
Drug-sensitive TBc	50	41–300	[8], [34], [35]
INH-resistant, non-MDR TBd	140	113–906	[8], [34], [35]
MDR-TBe	2,630	2,105–16,842	[8], [34], [35]
First-line ART (NNRTI-based), monthly	9	8–10	[36]
Second-line ART (PI-based), monthly	55	50–60	[36]

USD: US Dollars; TB: Tuberculosis; DOT: Directly Observed Therapy; 6EH: Six-month regimen of isoniazid plus ethambutol; 36H: Three-year regimen of isoniazid; 3RH: Three-month regimen of isoniazid plus rifampin; 3RPTH: Three-month regimen of isoniazid plus rifapentine; MDR: multidrug-resistant; ART: Antiretroviral Therapy; NNRTI: Non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor; 3RPTH: Three-month regimen of isoniazid plus rifapentine.

^aIncludes clinic visits, TB symptom screening quarterly, liver function tests every six months, and medications.

^bIncludes costs of acute presentation of TB (including inpatient and outpatient visits), plus TB treatment plus DOT.

^cCategory I (two-months intensive phase with isoniazid, rifampin, pyrazinamide, and ethambutol thrice-weekly, then four-months continuation phase with isoniazid and rifampin thrice-weekly) and DOT.

^dCategory I failure, followed by Category II treatment (three-months intensive phase with isoniazid, rifampin, pyrazinamide, and ethambutol thrice-weekly, with first two months including streptomycin thrice-weekly, then five-month continuation phase with isoniazid, rifampin and ethambutol thrice-weekly) and DOT.

^eCategory I and II failure, followed by MDRTB treatment (six-month intensive phase with streptomycin, ofloxacin, ethambutol, ethionamide, and pyrazinamide daily, followed by an eighteen-month of continuation phase with ofloxacin, ethambutol, ethionamide, and pyrazinamide daily) and DOT.